BioSpero

Based in South Korea, BioSpero develops advanced organ-on-chip technology to enhance biomedical research and drug testing, providing innovative solutions for studying human organ systems. BioSpero, founded in 2019 and headquartered in Jeju-si, South Korea, focuses on creating organ-on-chip systems that facilitate biomedical research. The company has successfully completed 2 deals, with the most recent investment occurring on February 23, 2026, when it raised KRW 1 billion from T. S.

Investment. BioSpero has raised a total of KRW 1 billion to date. BioSpero, Inc. specializes in advanced organ-on-chip technology, which aims to revolutionize biomedical research and drug testing.

Their core product offerings include the OrganXpert-M Pro, OrganXpert-O, and OrganXpert-T, designed to replicate human organ systems at a micro scale. These products utilize human cells in a controlled microenvironment, enabling researchers to study disease mechanisms, drug efficacy, and toxicology with high precision. Primary end users encompass pharmaceutical companies, academic institutions, and research organizations focused on drug development and personalized medicine. BioSpero's products are marketed in North America, Europe, and select Asian markets, establishing the company as a significant entity in the global biotechnology landscape.

BioSpero, Inc. generated revenue of KRW 301,830. 6 in 2024 through direct sales and strategic partnerships with research institutions and pharmaceutical companies. The company employs a B2B model, where clients purchase organ-on-chip systems for research and development purposes, often involving single purchases of flagship products such as the OrganXpert-M Pro along with potential service agreements for support and maintenance.

In February 2026, BioSpero raised KRW 1 billion in venture funding from T. S. Investment. The company plans to use these funds for its global expansion initiatives, particularly targeting the US and European markets.

This strategic direction aims to bolster BioSpero's presence and capability in key regions, enhancing its reach and operational footprint in the biotechnology sector.